CN113906140B - A2/ny-eso-1特异性t细胞受体及其用途 - Google Patents

A2/ny-eso-1特异性t细胞受体及其用途 Download PDF

Info

Publication number
CN113906140B
CN113906140B CN202080031738.8A CN202080031738A CN113906140B CN 113906140 B CN113906140 B CN 113906140B CN 202080031738 A CN202080031738 A CN 202080031738A CN 113906140 B CN113906140 B CN 113906140B
Authority
CN
China
Prior art keywords
tcr
cancer
cell
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080031738.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113906140A (zh
Inventor
G·库克斯
M·艾维英
V·佐埃特
O·米切林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of CN113906140A publication Critical patent/CN113906140A/zh
Application granted granted Critical
Publication of CN113906140B publication Critical patent/CN113906140B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
CN202080031738.8A 2019-03-18 2020-03-17 A2/ny-eso-1特异性t细胞受体及其用途 Active CN113906140B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
CN113906140A CN113906140A (zh) 2022-01-07
CN113906140B true CN113906140B (zh) 2025-01-28

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031738.8A Active CN113906140B (zh) 2019-03-18 2020-03-17 A2/ny-eso-1特异性t细胞受体及其用途

Country Status (7)

Country Link
US (2) US12473346B2 (https=)
EP (1) EP3941939A2 (https=)
JP (1) JP7680032B2 (https=)
CN (1) CN113906140B (https=)
AU (1) AU2020243431B2 (https=)
CA (1) CA3134102A1 (https=)
WO (1) WO2020188348A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4217738A1 (en) * 2020-09-27 2023-08-02 Genentech, Inc. High throughput multiparametric immune cell engager screening assay
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249606A (zh) * 2014-10-31 2017-10-13 宾夕法尼亚大学董事会 改变修饰的t细胞中的基因表达及其用途
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5617900A (en) 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249606A (zh) * 2014-10-31 2017-10-13 宾夕法尼亚大学董事会 改变修饰的t细胞中的基因表达及其用途
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Also Published As

Publication number Publication date
AU2020243431A1 (en) 2021-09-30
EP3941939A2 (en) 2022-01-26
US12473346B2 (en) 2025-11-18
WO2020188348A2 (en) 2020-09-24
US20220152109A1 (en) 2022-05-19
JP2022525925A (ja) 2022-05-20
JP7680032B2 (ja) 2025-05-20
US20260103503A1 (en) 2026-04-16
CA3134102A1 (en) 2020-09-24
WO2020188348A3 (en) 2020-12-17
CN113906140A (zh) 2022-01-07
AU2020243431B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
CN113906140B (zh) A2/ny-eso-1特异性t细胞受体及其用途
EP3490585B1 (en) Immunomodulatory polypeptides and related compositions and methods
US12187778B2 (en) Receptors providing targeted costimulation for adoptive cell therapy
JP2021072829A (ja) 治療用分子のｔ細胞送達のための組成物および方法
AU2015339106B2 (en) Compositions and methods of stimulating and expanding T cells
JP2019516350A (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
KR20170068598A (ko) 입양 세포 치료에서 복용을 위한 방법 및 조성물
WO2017190100A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP2017522893A (ja) Ｒｏｒ１特異的多重鎖キメラ抗原受容体
WO2019197676A1 (en) Heterodimeric inactivatable chimeric antigen receptors
CA3165827A1 (en) Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
EP4182336A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
JP2024509917A (ja) 腫瘍溶解性ウイルスによる直交性ｉｌ－２の送達を用いた、固形腫瘍におけるｔ細胞の選択的刺激方法
TW202306997A (zh) 用於在過繼細胞療法中提供標靶共刺激之受體
WO2023141530A2 (en) Receptors providing targeted costimulation for adoptive cell therapy
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
HK40058918A (en) A2/ny-eso-1 specific t cell receptors and uses thereof
JP2023536820A (ja) 二重ｃａｒ－ｔ細胞
HK40058918B (zh) A2/ny-eso-1特异性t细胞受体及其用途
CN116685602A (zh) 用于同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞
WO2024238938A1 (en) Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy
HK40100191A (zh) 用於同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞
HK40082776A (en) Anti-cd3 scfv and cytokine producing artificial antigen presenting cells
WO2021118873A1 (en) Method for preparing cd7-negative, cd3-positive t cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058918

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant